Story

UBS Downgrades Carl Zeiss Meditec to 'Sell' on China and Competition Headwinds

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
UBS Downgrades Carl Zeiss Meditec to 'Sell' on China and Competition Headwinds
Text size
Background

UBS downgraded German medical technology firm Carl Zeiss Meditec to 'sell' from 'neutral' on Tuesday, warning that a combination of Chinese healthcare reforms and intensifying competition threatens major segments of its business. The bank also slashed its 12-month price target for the company to €22.60 from €25.00.

China and Competition Risks Mount

Analysts at UBS highlighted that approximately 50% of the company's group sales are concentrated in four segments now facing worsening market conditions. The firm's significant historical growth, with a fourfold earnings expansion between 2011 and 2022, was heavily driven by its success in China, which now represents a concentrated risk.

China, which accounts for an estimated 24% of group sales, is introducing volume-based procurement reforms that could lead to price declines of 10%-20% on equipment. UBS identified several key pressure points:

  • China Refractive (8% of sales): Facing a new domestic challenge from FineVision, which is expected to launch a competing laser system in late 2027 or 2028.
  • DORC (10% of sales): Increased competition from rival Alcon's recently launched Unity VCS combination device.
  • Diagnostics (20% of sales): Facing what UBS called the "first meaningful competitive challenge" from Alcon's upcoming Unity Dx platform.

Earnings Forecasts and Valuation Concerns

Sample IUX Markets – In-articleAd

As a result of these headwinds, UBS projects the company's 2027 adjusted EBITA will be €185 million, roughly 20% below the consensus average of €234 million. The bank's longer-term forecast for 2029 is also pessimistic, implying a profit margin of 9.9%, well below management's target of over 15%.

Despite these risks, UBS noted that Carl Zeiss Meditec shares trade at a 30% premium to the medical technology sector. Analysts argued this valuation reflects "overly optimistic consensus expectations" that do not account for the emerging pressures on growth and profitability.

What It Means for Investors

The new price target implies a potential total return of negative 23.4%, comprising a 24.7% price decline and a 1.2% dividend yield, according to the bank's analysis. UBS stated it expects the company's fourth-quarter results, due on December 10, 2026, to include guidance that is "materially below consensus," potentially acting as a near-term catalyst for the stock.

Read next

More on Stocks
Back to latest news

LATEST